Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
NCT Number: NCT03451799
Enrolled subjects will be placed on a 16-week ketogenic diet (subject specific as prescribed by RD) while receiving standard of care cancer treatment (Radiation + Temozolomide). Study dietitians will create personalized meal plans for each patient with the goal of achieving and maintaining protocol defined metabolic ketosis. Subjects will be monitored for safety, nutrition, quality of life, and standard of care tumor assessments over the course of the study.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Los Angeles, California, 90048, United States
Enrolled subjects will be placed on a 16-week ketogenic diet (subject specific as prescribed by RD) while receiving standard of care cancer treatment (Radiation + Temozolomide). Study dietitians will place patients on a strict and controlled diet that manages daily macronutrient breakdown and increases the ratio of dietary fat relative to protein and carbohydrate consumption. Dietitians will provide guidance and teaching of the diet, as well as, monitoring and diet adjustment to ensure metabolic ketosis. Dietitians and study physicians (and their staff) will monitor subjects for safety, nutrition, quality of life, and standard of care tumor assessments over the course of the study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A 4-month ketogenic diet will be supervised and monitored by the study investigators. Study dietitians will create personalized meal plans for each patient with the goal of achieving and maintaining metabolic ketosis.
Patients will receive standard-of-care radiation. Radiation is not protocol directed.
Patients will receive standard-of-care temozolomide. Temozolomide is not protocol directed.
Time frame: Four Months
Proportion of participants experiencing a 10% decrease in weight or body mass index AND have a BMI <18.5 within one month from initiation of the ketogenic diet.
Time frame: Four months
Number of related adverse events based on CTCAE v.5.
Time frame: Four Months
Proportion of enrolled patients able to maintain blood ketone levels >0.3 mM for over 50% of days on study starting 2 weeks after initiation of the ketogenic diet.
Time frame: Sixty months
Time (in months) from initiation of the ketogenic diet to date of death
Time frame: Four Months
Time (in months) from baseline to progressive disease over study duration (estimated 4 months)
Time frame: Two months
Mean change in overall Quality of Life from baseline to two months.
-Quality of Life measured using EORTC QLQ-C30 global score
Time frame: Four months
Mean change in overall Quality of Life from baseline to four months.
-Quality of Life measured using EORTC QLQ-C30 global score
Time frame: Four months
Mean change in cognitive function from initiation of ketogenic diet to four months.
-measured using Hopkins Verbal learning Test-Revised
Time frame: Four months
Mean change in cognitive function from initiation of ketogenic diet to four months.
-measured using Trail Making Test
Time frame: Four months
Mean change in cognitive function from initiation of ketogenic diet to four months.
-measured using Controlled Word Association Test
Time frame: Four months
Mean change in cognitive function from initiation of ketogenic diet to four months.
-measured using Montreal Cognitive Assessment
Jethro Hu
Other
IIT2016-17-HU-KETORADTMZ: A Phase 1 Study of a 4-month Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Newly/Recently Diagnosed Glioblastoma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03630289
Astrocytoma, Brain Cancer
New York, United States
View Trial DetailsNCT04391595
Astrocytoma, GBM
Chandler, Arizona, United States
View Trial DetailsNCT03426891
Astrocytoma, Brain Diseases
Tampa, Florida, United States
View Trial DetailsNCT03050736
Astrocytoma, Brain Cancer
Guangzhou, China
View Trial Details